John R Wunderlich
Overview
Explore the profile of John R Wunderlich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
13462
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parkhurst M, Robbins P, Tran E, Prickett T, Gartner J, Jia L, et al.
Cancer Discov
. 2019 Jun;
9(8):1022-1035.
PMID: 31164343
Immunotherapies can mediate regression of human tumors with high mutation rates, but responses are rarely observed in patients with common epithelial cancers. This raises the question of whether patients with...
2.
Stevanovic S, Helman S, Wunderlich J, Langhan M, Doran S, Kwong M, et al.
Clin Cancer Res
. 2018 Dec;
25(5):1486-1493.
PMID: 30518633
Purpose: Cellular therapy is an emerging cancer treatment modality, but its application to epithelial cancers has been limited. This clinical trial evaluated tumor-infiltrating lymphocyte (TIL) therapy for the treatment of...
3.
Deniger D, Pasetto A, Robbins P, Gartner J, Prickett T, Paria B, et al.
Clin Cancer Res
. 2018 Jun;
24(22):5562-5573.
PMID: 29853601
This was a study prospectively evaluating intratumoral T-cell responses to autologous somatic mutated neoepitopes expressed by human metastatic ovarian cancers. Tumor-infiltrating lymphocytes (TIL) were expanded from resected ovarian cancer metastases,...
4.
Chandran S, Somerville R, Yang J, Sherry R, Klebanoff C, Goff S, et al.
Lancet Oncol
. 2017 Apr;
18(6):792-802.
PMID: 28395880
Background: Uveal melanoma is a rare tumour with no established treatments once metastases develop. Although a variety of immune-based therapies have shown efficacy in metastatic cutaneous melanoma, their use in...
5.
Assadipour Y, Zacharakis N, Crystal J, Prickett T, Gartner J, Somerville R, et al.
Clin Cancer Res
. 2017 Apr;
23(15):4347-4353.
PMID: 28377481
The administration of autologous tumor-infiltrating lymphocytes (TILs) can mediate durable tumor regressions in patients with melanoma likely based on the recognition of immunogenic somatic mutations expressed by the cancer. There...
6.
Deniger D, Kwong M, Pasetto A, Dudley M, Wunderlich J, Langhan M, et al.
Clin Cancer Res
. 2017 Jan;
23(2):351-362.
PMID: 28093487
Purpose: This pilot feasibility clinical trial evaluated the coadministration of vemurafenib, a small-molecule antagonist of BRAF mutations, and tumor-infiltrating lymphocytes (TIL) for the treatment of metastatic melanoma. Experimental Design: A...
7.
Goff S, Dudley M, Citrin D, Somerville R, Wunderlich J, Danforth D, et al.
J Clin Oncol
. 2016 May;
34(20):2389-97.
PMID: 27217459
Purpose: Adoptive cell transfer, the infusion of large numbers of activated autologous lymphocytes, can mediate objective tumor regression in a majority of patients with metastatic melanoma (52 of 93; 56%)....
8.
Gros A, Parkhurst M, Tran E, Pasetto A, Robbins P, Ilyas S, et al.
Nat Med
. 2016 Feb;
22(4):433-8.
PMID: 26901407
Detection of lymphocytes that target tumor-specific mutant neoantigens--derived from products encoded by mutated genes in the tumor--is mostly limited to tumor-resident lymphocytes, but whether these lymphocytes often occur in the...
9.
Rothermel L, Sabesan A, Stephens D, Chandran S, Paria B, Srivastava A, et al.
Clin Cancer Res
. 2015 Dec;
22(9):2237-49.
PMID: 26712692
Purpose: Uveal melanoma is a rare melanoma variant with no effective therapies once metastases develop. Although durable cancer regression can be achieved in metastatic cutaneous melanoma with immunotherapies that augment...
10.
Tran E, Ahmadzadeh M, Lu Y, Gros A, Turcotte S, Robbins P, et al.
Science
. 2015 Oct;
350(6266):1387-90.
PMID: 26516200
It is unknown whether the human immune system frequently mounts a T cell response against mutations expressed by common epithelial cancers. Using a next-generation sequencing approach combined with high-throughput immunologic...